Pharmaceutical News and Articles

EBCC: Axillary Radiotherapy Without Lymphadenectomy Feasible for Breast Cancer

For patients with breast cancer with limited nodal disease after neoadjuvant therapy, axillary radiotherapy (ART) is as effective as axillary lymphadenectomy (A

Online Tool Enables Communication of Genetic Testing Results With Family Members

A new online tool may help cancer patients communicate genetic testing results with family, according to a study published online March 24 in the Journal of Cli

More Than 250,000 Global Deaths From Meningitis Reported in 2023

In 2023, there were 259,000 global deaths and 2.54 million incident cases of meningitis, according to a study published online March 27 in The Lancet Neurology.

Major Cardiovascular Event Risk Increased With Discontinuation of GLP-1 RAs in T2D

For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for major adverse

Repatha Cuts Risk of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis

Amgen (NASDAQ AMGN) announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, r

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Priovant Therapeutics, a clinical-stage biotechnology company focused on developing targeted therapeutics in autoimmune disease, announced today the publication

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for Winrevair (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck (NYSE MRK), known as MSD outside of the United States and Canada, today announced detailed results from the Phase 2 CADENCE study, which was designed to e

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb (NYSE BMY) today announced positive data from the Phase 3 SCOUT-HCM trial of Camzyos (mavacamten), the first study of a cardiac myosin inhi

Novartis IgAN data in New England Journal of Medicine Show Fabhalta Slowed Kidney Function Decline by 49.3%

Basel, March 29, 2026 Novartis today announced final two-year results from the Phase III APPLAUSE IgAN study of Fabhalta (iptacopan) in IgA nephropathy (IgAN).

FDA Approves Awiqli (insulin icodec-abae) as the First and Only Once-Weekly Basal Insulin Treatment for Adults with Type 2 Diabetes